P. Greipp, K. Jafallon, W. Kyle, and R. , Value of beta 2- microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma, Blood, vol.72, pp.219-223, 1988.

B. Drewinko and R. Alexanian, Growth Kinetics of Plasma Cell Myeloma 2, JNCI: Journal of the National Cancer Institute, vol.58, issue.5, p.1247, 1977.
DOI : 10.1093/jnci/58.5.1247

M. Slifka, R. Antia, J. Whitmire, and R. Ahmed, Humoral Immunity Due to Long-Lived Plasma Cells, Immunity, vol.8, issue.3, pp.363-372, 1998.
DOI : 10.1016/S1074-7613(00)80541-5
URL : http://doi.org/10.1016/s1074-7613(00)80541-5

P. Merville, J. Dechanet, A. Desmouliere, I. Durand, O. Debouteiller et al., Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts, Journal of Experimental Medicine, vol.183, issue.1, pp.227-236, 1996.
DOI : 10.1084/jem.183.1.227
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192413

Z. Gu, J. Vos, C. Rebouissou, J. M. Zhang, X. Rossi et al., Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors, Leukemia, vol.14, issue.1, pp.188-197, 2000.
DOI : 10.1038/sj.leu.2401632

X. Zhang, Z. Gu, Z. Lu, K. Yasukawa, G. Yancopoulos et al., Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130, Journal of Experimental Medicine, vol.179, issue.4, pp.1337-1342, 1994.
DOI : 10.1084/jem.179.4.1337

N. Nishimoto, A. Ogata, Y. Shima, Y. Tani, H. Ogawa et al., Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130, Journal of Experimental Medicine, vol.179, issue.4, pp.1343-1347, 1994.
DOI : 10.1084/jem.179.4.1343

J. Westendorf and D. Jelinek, Growth regulatory pathways in myeloma. Evidence of autocrine oncostatin M expression, J Immunol, vol.157, pp.3081-3088, 1996.

M. Ferlin-bezombes, J. M. Liautard, J. Brochier, J. Rossi, J. Klein et al., IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis, J Immunol, vol.161, pp.2692-2699, 1998.

P. Liu, M. Oken, V. Ness, and B. , Interferon-?? protects myeloma cell lines from dexamethasone-induced apoptosis, Leukemia, vol.13, issue.3, pp.473-480, 1999.
DOI : 10.1038/sj.leu.2401334

F. Xu, A. Gardner, Y. Tu, P. Michl, D. Prager et al., Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors, British Journal of Haematology, vol.97, issue.2, pp.429-440, 1997.
DOI : 10.1046/j.1365-2141.1997.592708.x

P. Georgii-hemming, H. Wiklund, O. Ljunggren, and K. Nilsson, Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines, Blood, vol.88, pp.2250-2258, 1996.

M. Ferlin, N. Noraz, C. Hertogh, J. Brochier, N. Taylor et al., Insulin-like growth factor induces the survival and proliferation of myeloma cells through an IL-6- independent transduction pathway, Br J Haematol, 2000.

A. Gross, J. Mcdonnell, and S. Korsmeyer, BCL-2 family members and the mitochondria in apoptosis, Genes & Development, vol.13, issue.15, pp.1899-1911, 1999.
DOI : 10.1101/gad.13.15.1899

J. Adams and C. S. , The Bcl-2 Protein Family: Arbiters of Cell Survival, Science, vol.281, issue.5381, pp.1322-1326, 1998.
DOI : 10.1126/science.281.5381.1322

S. Takayama, T. Sato, S. Krajewski, K. Kochel, S. Irie et al., Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity, Cell, vol.80, issue.2, pp.279-284, 1995.
DOI : 10.1016/0092-8674(95)90410-7

M. Hamilton, H. Barker, J. Ball, M. Drew, S. Abbot et al., Normal and neoplastic human plasma cells express bcl-2 antigen, Leukemia, vol.5, pp.768-771, 1991.

M. Pettersson, H. Jernberg-wiklund, L. Larsson, C. Sundstrom, I. Givol et al., Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells, Blood, vol.79, pp.495-502, 1992.

F. Ong, J. Nieuwkoop, G. Degrootswings, J. Hermans, M. Harvey et al., Bcl-2 protein expression is not related to short survival in multiple myeloma, Leukemia, vol.9, pp.1282-1284, 1995.

N. Harada, H. Hata, M. Yoshida, T. Soniki, A. Nagasaki et al., Expression of Bcl-2 family of proteins in fresh myeloma cells, Leukemia, vol.12, issue.11, pp.1817-1820, 1998.
DOI : 10.1038/sj.leu.2401168

D. Puthier, C. Pellat-deceunynck, S. Barille, N. Robillard, M. Rapp et al., Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy, Leukemia, vol.13, issue.2, pp.289-294, 1999.
DOI : 10.1038/sj.leu.2401302

A. Lichtenstein, Y. Tu, C. Fady, R. Vescio, and J. Berenson, Interleukin-6 Inhibits Apoptosis of Malignant Plasma Cells, Cellular Immunology, vol.162, issue.2, pp.248-255, 1995.
DOI : 10.1006/cimm.1995.1076

M. Schwarze and R. Hawley, Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-x(L), Cancer Res, vol.55, pp.2262-2265, 1995.

D. Puthier, S. Derenne, S. Barille, P. Moreau, J. Harousseau et al., Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells, British Journal of Haematology, vol.88, issue.2, pp.392-395, 1999.
DOI : 10.1083/jcb.128.6.1173

R. Catlett-falcone, T. Landowski, M. Oshiro, J. Turkson, A. Levitzki et al., Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells, Immunity, vol.10, issue.1, pp.105-115, 1999.
DOI : 10.1016/S1074-7613(00)80011-4

Y. Tu, S. Renner, F. Xu, A. Fleishman, J. Taylor et al., BCL-X expression in multiple myeloma: possible indicator of chemoresistance, Cancer Res, vol.58, pp.256-262, 1998.

F. Xu, S. Sharma, A. Gardner, Y. Tu, A. Raitano et al., Interleukin-6-induced inhibition of multiple myeloma cell apoptosis, 1998.

X. Zhang, J. Gaillard, N. Robillard, Z. Lu, Z. Gu et al., Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma, Blood, vol.83, pp.3654-3663, 1994.

I. Vermes, C. Haanen, H. Steffens-nakken, and C. Reutelingsperger, A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V, Journal of Immunological Methods, vol.184, issue.1, pp.39-51, 1995.
DOI : 10.1016/0022-1759(95)00072-I

C. Kayalar, T. Ord, M. Testa, L. Zhong, and D. Bredesen, Cleavage of actin by interleukin 1 beta-converting enzyme to reverse DNase I inhibition., Proceedings of the National Academy of Sciences, vol.93, issue.5, pp.2234-2238, 1996.
DOI : 10.1073/pnas.93.5.2234

M. Knodel, A. Kuss, D. Lindemann, I. Berberich, and A. Schimpl, Reversal of Blimp-1-mediated apoptosis by A1, a member of the Bcl-2 family, European Journal of Immunology, vol.22, issue.9, pp.2988-2998, 1999.
DOI : 10.1002/(SICI)1521-4141(199909)29:09<2988::AID-IMMU2988>3.0.CO;2-T

J. Lomo, E. Smeland, S. Krajewski, J. Reed, and H. Blomhoff, Expression of the bcl-2 homologue mcl-1 correlates with survival of peripheral blood b lymphocytes, Cancer Res, vol.56, pp.40-43, 1996.

D. Moulding, J. Quayle, C. Hart, and S. Edwards, Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival, Blood, vol.92, pp.2495-2502, 1998.

P. Zhou, L. Qian, K. Kozopas, and R. Craig, Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions, Blood, vol.89, pp.630-643, 1997.

P. Zhou, L. Qian, C. Bieszczad, N. R. Binder, M. Levy et al., Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage, Blood, vol.92, pp.3226-3239, 1998.

A. Ogata, D. Chauhan, G. Teoh, S. Treon, M. Urashima et al., IL-6 triggers cell growth via the Ras-dependent mitogenactivated protein kinase cascade, J Immunol, vol.159, pp.2212-2221, 1997.

D. Jelinek, K. Aagaard-tillery, B. Arendt, T. Arora, R. Tschumper et al., Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression., Journal of Clinical Investigation, vol.99, issue.3, pp.447-456, 1997.
DOI : 10.1172/JCI119179
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC507818

L. Berger, T. Hawley, J. Lust, S. Goldman, and R. Hawley, Tyrosine Phosphorylation of Jak-Tyk Kinases in Malignant Plasma Cell Lines Growth Stimulated by Interleukins 6 and 11, Biochemical and Biophysical Research Communications, vol.202, issue.1, pp.596-605, 1994.
DOI : 10.1006/bbrc.1994.1970

D. Puthier, R. Bataille, and M. Amiot, IL-6 up-regulates Mcl-1 in human myeloma cells through JAK???/???STAT rather than Ras???/???MAP kinase pathway, European Journal of Immunology, vol.161, issue.12, pp.3945-3950, 1999.
DOI : 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O

D. Vos, J. , J. M. Tarte, K. Jasmin, C. Klein et al., JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells, Br J Haematol, 2000.

M. Jourdan, M. Ferlin, E. Legouffe, M. Horvathova, J. Liautard et al., The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells, British Journal of Haematology, vol.83, issue.4, pp.637-646, 1998.
DOI : 10.1046/j.1365-2141.1996.d01-1811.x